Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hunt

Showing results (651-660 of 671) with videos related to

Pageof 68
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
Journal of Medicinal Chemistry|February 22, 2008
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)Zhen-wei Cai, Yongzheng Zhang, Robert M Borzilleri, et al.
Journal of Medicinal Chemistry|January 5, 1996
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activityK Leftheris, T Kline, G D Vite, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1Emily C Cherney, Liping Zhang, Susheel Nara, et al.
The International Journal of Behavioral Nutrition and Physical Activity|February 11, 2021
Children's moderate-to-vigorous physical activity on weekdays versus weekend days: a multi-country analysisKeith Brazendale, Michael W Beets, Bridget Armstrong, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
The Lancet. Microbe|May 2, 2026
High-throughput multiplex immunoassay for the detection of mpox and MVA-BN vaccination up to 2 years after exposure in Belgium: a retrospective diagnostic accuracy studyJoachim Mariën, Christophe Van Dijck, Nicole Berens-Riha, et al.
Pageof 68

Showing results (651-660 of 671) with videos related to

Sort By:
Pageof 68
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
Journal of Medicinal Chemistry|February 22, 2008
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)Zhen-wei Cai, Yongzheng Zhang, Robert M Borzilleri, et al.
Journal of Medicinal Chemistry|January 5, 1996
Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activityK Leftheris, T Kline, G D Vite, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
ACS Medicinal Chemistry Letters|February 19, 2021
Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1Emily C Cherney, Liping Zhang, Susheel Nara, et al.
The International Journal of Behavioral Nutrition and Physical Activity|February 11, 2021
Children's moderate-to-vigorous physical activity on weekdays versus weekend days: a multi-country analysisKeith Brazendale, Michael W Beets, Bridget Armstrong, et al.
Journal of Medicinal Chemistry|March 31, 2006
Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitorRajeev S Bhide, Zhen-Wei Cai, Yong-Zheng Zhang, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
The Lancet. Microbe|May 2, 2026
High-throughput multiplex immunoassay for the detection of mpox and MVA-BN vaccination up to 2 years after exposure in Belgium: a retrospective diagnostic accuracy studyJoachim Mariën, Christophe Van Dijck, Nicole Berens-Riha, et al.
Pageof 68